Hyderabad-based NATCO Pharma has recorded consolidated total revenue of Rs 2078.9 crore for the year ended on March 31, 2017, as against Rs 1089.7 crore for the last year, reflecting a year-over-year growth of 90.8 per cent. The net profit for the period, on a consolidated basis, was Rs 486 crore, as against Rs 157.1 crore last year, showing a growth of 209.3 per cent.

For the fourth quarter (Q4) ended March 31, 2017, the company recorded a net revenue of Rs 577.2 crore, on a consolidated basis, as against Rs 394.8 crore during Q4, FY 2016, posting an increase of 46.2 per cent. The profit after tax, on a consolidated basis, was recorded as Rs 176.7 crore for the quarter, as against Rs 62.8 crore same quarter last year, showing a growth of 181.4 per cent.

The revenue and profit growth for the company during the financial year was driven primarily due to the sales of generic Oseltamivir product in the US market and continued growth of domestic formulations business.